From the Peking University People's Hospital, Department of Anaesthesiology, Beijing, China (QZ, YW, HA, YF).
Eur J Anaesthesiol. 2023 Aug 1;40(8):552-559. doi: 10.1097/EJA.0000000000001856. Epub 2023 May 23.
Perioperative use of opioids has revealed significant adverse effects associated with poor postoperative outcomes.
To determine whether opioid-free anaesthesia based on thoracic paravertebral block (TPVB) could improve postoperative recovery after breast cancer surgery.
A randomised controlled trial.
A tertiary teaching hospital.
Eighty adult women undergoing breast cancer surgery were enrolled. Key exclusion criteria included remote metastasis (but not to axillary lymph nodes of the surgical side), contraindication to interventions or drugs and a history of chronic pain or chronic opioid use.
Eligible patients were randomised at a 1 : 1 ratio to receive either TPVB-based opioid-free anaesthesia (OFA group) or opioid-based anaesthesia (control group).
The primary outcome was the global score of the 15-item Quality of Recovery (QoR-15) questionnaire at 24 h after surgery. Secondary outcomes included postoperative pain and health-related quality of life.
The QoR-15 global score was 140.3 ± 5.2 in the OFA group and 132.0 ± 12.0 in the control group ( P < 0.001). The percentage of patients with good recovery (QoR-15 global score ≥118) was 100% (40/40) in the OFA group and 82.5% (33/40) in the control group ( P = 0.012). Improved QoR in the OFA group was also evident in sensitivity analysis that rated QoR as excellent for a score of 136 to 150, as good at 122 to 135, as moderate at 90 to 121 and as poor at 0 to 89. The OFA group had higher scores in the domains of physical comfort (45.7 ± 3.0 versus 41.8 ± 5.7, P < 0.001) and physical independence (18.3 ± 2.2 versus 16.3 ± 4.5, P = 0.014). The two groups did not differ in pain outcomes or health-related quality of life.
TPVB-based opioid-free anaesthesia improved early postoperative quality of recovery without compromising pain control in patients undergoing breast cancer surgery.
Clinicaltrials.gov; Identifier: NCT04390698.
围手术期使用阿片类药物与术后不良结局相关,已显现出显著的不良反应。
确定基于胸椎旁神经阻滞(TPVB)的无阿片类药物麻醉是否可以改善乳腺癌手术后的恢复。
随机对照试验。
一家三级教学医院。
80 名接受乳腺癌手术的成年女性入组。主要排除标准包括远处转移(但不包括手术侧腋窝淋巴结)、干预或药物禁忌证以及慢性疼痛或慢性阿片类药物使用史。
符合条件的患者以 1:1 的比例随机分为接受基于 TPVB 的无阿片类药物麻醉(OFA 组)或基于阿片类药物的麻醉(对照组)。
主要结局为术后 24 小时 15 项恢复质量(QoR-15)问卷的总体评分。次要结局包括术后疼痛和健康相关生活质量。
OFA 组 QoR-15 总体评分为 140.3±5.2,对照组为 132.0±12.0(P<0.001)。OFA 组中恢复良好(QoR-15 总体评分≥118)的患者百分比为 100%(40/40),对照组为 82.5%(33/40)(P=0.012)。OFA 组的 QoR 改善也在 QoR 评分 136-150 为优秀、122-135 为良好、90-121 为中等、0-89 为差的敏感性分析中得到证实。OFA 组在身体舒适度(45.7±3.0 比 41.8±5.7,P<0.001)和身体独立性(18.3±2.2 比 16.3±4.5,P=0.014)方面的评分更高。两组在疼痛结局或健康相关生活质量方面无差异。
基于 TPVB 的无阿片类药物麻醉可改善乳腺癌手术患者的早期术后恢复质量,而不会影响疼痛控制。
Clinicaltrials.gov;标识符:NCT04390698。